Hey Tada, While I would agree that preserving capital at this point is very important I still think that it is just as important that management get some business done to support the expanding the forward progress of the science programs. The once again delayed BETonRenal trial is for those on dialysis and is a wholly CKD trial. Management told us long ago that this was a short, inexpensive trial and CKD is an enormous opportunity. Wouldn’t it be nice to have the trial for those on dialysis complete by the read out for BETonMACE with its CKD subgroup?  Assuming both the BETonRenal and the BoM CKD results are positive, this would be huge for the company. Additionally, if the scope of BETonMACE is expanded then I think being underway in BETonRenal would be supportive to a stock which would likely be under increased pressure in the event of extending BoM. 

Kelsee, firstly thank you for the great job you and the others do managing this hub. While I agree that things will unfold to the company’s timeline and not ours I think management needs to do a much better job at accurately communicating those timelines and managing investors expectations. I have trouble remembering the last time we were told something was in the works and it actually happened in the timeframe as per guidance given. I understand and feel the frustration of others.  I think everyone here understands the risks inherent to biotech. Good management should provide good execution, clear communication and in general be managing to keep the risks involved down to the science. Management at RVX has rarely achieved this in my opinion.